Author: AlShehry, Nawal; Zaidi, Syed Ziauddin A; AlAskar, Ahmed; Al Odayani, Abdurahman; Alotaibi, Jawaher Mubarak; AlSagheir, Ahmed; Al-Eyadhy, Ayman; Balelah, Saud; Salam, Abdul; Zaidi, Abdul Rehman Zia; Alawami, Diea; Alshahrani, Mohammed S.; AlMozain, Nour; Abulhamayel, Yem M; Al Qunfoidi, Reem; Alfaraj, Mona; Qushmaq, Nahid; Alansari, Rehab; Dayel, Afra; Elgohary, Ghada; Al Bahrani, Ahmed; Nabhan Abdelhameed, Arwa A.; AlZahrani, Hazza Abdullah; Alturkistani, Hanan; AlShehry, Nada; Albalawi, Mohammed Abdulhameed; Elalfy, Ibrahim; Alhumaidan, Hind; Al-Hashmi, Hani
Title: Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia Cord-id: xnp93hfh Document date: 2020_12_26
ID: xnp93hfh
Snippet: OBJECTIVE: To present the interim findings from a national study investigating the safety and efficacy of convalescent plasma (CP) containing detectable IgG antibodies as a treatment strategy for severe coronavirus disease 2019 (COVID-19). TRIAL DESIGN AND PARTICIPANTS: An open label, two-arm, phase-II clinical trial conducted across 22 hospitals from Saudi Arabia. The intervention group included 40 adults (aged ≥18 years) with confirmed severe COVID-19 and the control group included 124 patie
Document: OBJECTIVE: To present the interim findings from a national study investigating the safety and efficacy of convalescent plasma (CP) containing detectable IgG antibodies as a treatment strategy for severe coronavirus disease 2019 (COVID-19). TRIAL DESIGN AND PARTICIPANTS: An open label, two-arm, phase-II clinical trial conducted across 22 hospitals from Saudi Arabia. The intervention group included 40 adults (aged ≥18 years) with confirmed severe COVID-19 and the control group included 124 patients matched using propensity score for age, gender, intubation status, and history of diabetes and/or hypertension. Intervention group included those (a) with severe symptoms (dyspnea; respiratory rate, ≥30/min; SpO(2), ≤93%, PaO2/FiO2 ratio, <300; and/or lung infiltrates >50% within 24–48 h), (b) requiring intensive care unit (ICU) care or (c) experiencing life-threatening conditions. The control group included confirmed severe COVID-19 patients of similar characteristics who did not consent for CP infusion or were not able to receive CP due to its nonavailability. INTERVENTIONS: The intervention group participants were infused 300 ml (200–400 ml/treatment dose) CP at least once, and if required, daily for up to 5 sessions, along with receiving the best standard of care. The control group only received the best standard of care. OUTCOMES: The primary endpoints were safety and ICU length of stay (LOS). The secondary endpoints included 30-day mortality, days on mechanical ventilation and days to clinical recovery. RESULTS: CP transfusion did not result in any adverse effects. There was no difference in the ICU LOS (median 8 days in both groups). The mortality risk was lower in the CP group: 13% absolute risk reduction (P = 0.147), hazard ratio (95% confidence interval): 0.554 (0.299–1.027; P = 0.061) by log-rank test. There was no significant difference in the days on mechanical ventilation and days to clinical recovery. CONCLUSION: CP containing detectable antibodies is a safe strategy and may result in a decrease in mortality in patients with severe COVID-19. The results of the completed trial with a larger study sample would provide more clarity if this difference in mortality is significant. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04347681; Saudi Clinical Trials Registry No.: 20041102.
Search related documents:
Co phrase search for related documents- absolute reduction and lymphocyte count: 1, 2
- acute trali lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- admission date and los stay length: 1, 2, 3, 4, 5, 6, 7, 8
- admission date and lymphocyte count: 1, 2, 3
- admission time and los stay length: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- admission time and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- admission time and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- admission time and lymphocyte elevation: 1
- los stay length and lung injury: 1, 2, 3
- los stay length and lymphocyte count: 1, 2
- lung injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Co phrase search for related documents, hyperlinks ordered by date